A detailed history of Kestra Advisory Services, LLC transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Kestra Advisory Services, LLC holds 16,100 shares of AVDL stock, worth $226,366. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,100
Previous 23,150 30.45%
Holding current value
$226,366
Previous $326,000 16.87%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$12.55 - $17.22 $88,477 - $121,400
-7,050 Reduced 30.45%
16,100 $271,000
Q4 2023

Feb 14, 2024

BUY
$9.64 - $14.59 $11,568 - $17,508
1,200 Added 5.47%
23,150 $326,000
Q3 2023

Nov 09, 2023

BUY
$10.3 - $15.99 $15,450 - $23,985
1,500 Added 7.33%
21,950 $226,000
Q2 2023

Aug 11, 2023

BUY
$8.48 - $16.48 $54,696 - $106,296
6,450 Added 46.07%
20,450 $337,000
Q1 2023

May 12, 2023

SELL
$6.41 - $9.95 $10,576 - $16,417
-1,650 Reduced 10.54%
14,000 $128,000
Q4 2022

Jan 31, 2023

SELL
$5.73 - $10.0 $179,062 - $312,500
-31,250 Reduced 66.63%
15,650 $112,000
Q3 2022

Nov 01, 2022

BUY
$2.57 - $7.31 $42,405 - $120,615
16,500 Added 54.28%
46,900 $235 Million
Q2 2022

Aug 12, 2022

SELL
$1.07 - $6.95 $17,280 - $112,242
-16,150 Reduced 34.69%
30,400 $74,000
Q1 2022

Apr 26, 2022

BUY
$5.46 - $8.29 $70,434 - $106,940
12,900 Added 38.34%
46,550 $317,000
Q4 2021

Jan 20, 2022

BUY
$7.34 - $11.18 $173,591 - $264,407
23,650 Added 236.5%
33,650 $271,000
Q1 2021

May 10, 2021

SELL
$6.61 - $10.07 $112 - $171
-17 Reduced 0.17%
10,000 $90,000
Q4 2020

Jan 20, 2021

BUY
$5.03 - $7.95 $85 - $135
17 Added 0.17%
10,017 $67 Million
Q3 2020

Nov 12, 2020

BUY
$5.02 - $8.98 $50,199 - $89,800
10,000 New
10,000 $50 Million

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $852M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Kestra Advisory Services, LLC Portfolio

Follow Kestra Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kestra Advisory Services, LLC with notifications on news.